JP6878473B2 - ブリンシドフォビルの製剤 - Google Patents

ブリンシドフォビルの製剤 Download PDF

Info

Publication number
JP6878473B2
JP6878473B2 JP2018568195A JP2018568195A JP6878473B2 JP 6878473 B2 JP6878473 B2 JP 6878473B2 JP 2018568195 A JP2018568195 A JP 2018568195A JP 2018568195 A JP2018568195 A JP 2018568195A JP 6878473 B2 JP6878473 B2 JP 6878473B2
Authority
JP
Japan
Prior art keywords
concentration
pharmaceutical composition
solution
mannitol
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018568195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519570A (ja
JP2019519570A5 (enExample
Inventor
ムハンマド アナウルル カビール
ムハンマド アナウルル カビール
オーディン ヨハン ナデレル
オーディン ヨハン ナデレル
イルマ マリサ グローシー
イルマ マリサ グローシー
Original Assignee
キメリックス インコーポレイテッド
キメリックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キメリックス インコーポレイテッド, キメリックス インコーポレイテッド filed Critical キメリックス インコーポレイテッド
Publication of JP2019519570A publication Critical patent/JP2019519570A/ja
Publication of JP2019519570A5 publication Critical patent/JP2019519570A5/ja
Priority to JP2021075612A priority Critical patent/JP7221485B2/ja
Application granted granted Critical
Publication of JP6878473B2 publication Critical patent/JP6878473B2/ja
Priority to JP2023005643A priority patent/JP7407984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018568195A 2016-06-28 2017-06-28 ブリンシドフォビルの製剤 Active JP6878473B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021075612A JP7221485B2 (ja) 2016-06-28 2021-04-28 ブリンシドフォビルの製剤
JP2023005643A JP7407984B2 (ja) 2016-06-28 2023-01-18 ブリンシドフォビルの製剤

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662355844P 2016-06-28 2016-06-28
US62/355,844 2016-06-28
US201662394665P 2016-09-14 2016-09-14
US62/394,665 2016-09-14
US201762446213P 2017-01-13 2017-01-13
US62/446,213 2017-01-13
US201762465053P 2017-02-28 2017-02-28
US62/465,053 2017-02-28
US201762507397P 2017-05-17 2017-05-17
US62/507,397 2017-05-17
US201762512825P 2017-05-31 2017-05-31
US62/512,825 2017-05-31
PCT/US2017/039804 WO2018005676A1 (en) 2016-06-28 2017-06-28 Formulations of brincidofovir

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021075612A Division JP7221485B2 (ja) 2016-06-28 2021-04-28 ブリンシドフォビルの製剤

Publications (3)

Publication Number Publication Date
JP2019519570A JP2019519570A (ja) 2019-07-11
JP2019519570A5 JP2019519570A5 (enExample) 2020-02-20
JP6878473B2 true JP6878473B2 (ja) 2021-05-26

Family

ID=59313330

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018568195A Active JP6878473B2 (ja) 2016-06-28 2017-06-28 ブリンシドフォビルの製剤
JP2021075612A Active JP7221485B2 (ja) 2016-06-28 2021-04-28 ブリンシドフォビルの製剤
JP2023005643A Active JP7407984B2 (ja) 2016-06-28 2023-01-18 ブリンシドフォビルの製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021075612A Active JP7221485B2 (ja) 2016-06-28 2021-04-28 ブリンシドフォビルの製剤
JP2023005643A Active JP7407984B2 (ja) 2016-06-28 2023-01-18 ブリンシドフォビルの製剤

Country Status (12)

Country Link
US (3) US20170368082A1 (enExample)
EP (2) EP4295853A3 (enExample)
JP (3) JP6878473B2 (enExample)
CN (4) CN118416082A (enExample)
AU (2) AU2017290703B2 (enExample)
CA (1) CA3024886A1 (enExample)
DK (1) DK3474822T3 (enExample)
ES (1) ES3037596T3 (enExample)
FI (1) FI3474822T3 (enExample)
PL (1) PL3474822T3 (enExample)
PT (1) PT3474822T (enExample)
WO (1) WO2018005676A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143178A (ja) * 2016-06-28 2021-09-24 キメリックス インコーポレイテッド ブリンシドフォビルの製剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073148A1 (en) 2013-11-15 2015-05-21 Chimerix Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途
CN114558022B (zh) * 2022-02-16 2023-11-17 华中农业大学 布林西多福韦在制备抗伪狂犬病毒药物中的应用
CN114732821A (zh) * 2022-04-24 2022-07-12 华中农业大学 西多福韦的前药在制备防治非洲猪瘟药物中的应用
JP7417339B1 (ja) * 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
WO2025072782A1 (en) * 2023-09-29 2025-04-03 Symbio Pharmaceuticals Limited Brincidofovir for treatment of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005490A (es) 1999-12-03 2004-09-10 Univ California San Diego Compuestos de fosfonato.
JP4136340B2 (ja) * 2000-08-18 2008-08-20 武田薬品工業株式会社 注射剤
JP2008538354A (ja) 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2010525063A (ja) * 2007-04-27 2010-07-22 キメリクス，インコーポレイテッド ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
JP2011116658A (ja) 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
AU2010279678B2 (en) 2009-08-03 2015-09-10 Emergent Biodefense Operations Lansing Llc Composition and methods of treating viral infections and viral induced tumors
CA2779473C (en) 2009-10-30 2016-08-16 Chimerix, Inc. Methods of treating viral associated diseases
ES2547698T3 (es) 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Liposoma de irinotecán o su clorhidrato y método de preparación del mismo
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
CN103209985B (zh) 2010-08-31 2016-08-24 奇默里克斯公司 膦酸酯衍生物及其合成方法
EP2770834A4 (en) * 2011-10-26 2015-11-25 Chimerix Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
WO2013163509A1 (en) 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015073148A1 (en) * 2013-11-15 2015-05-21 Chimerix Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters
CN118416082A (zh) * 2016-06-28 2024-08-02 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143178A (ja) * 2016-06-28 2021-09-24 キメリックス インコーポレイテッド ブリンシドフォビルの製剤

Also Published As

Publication number Publication date
ES3037596T3 (en) 2025-10-03
WO2018005676A1 (en) 2018-01-04
PT3474822T (pt) 2025-08-21
CN118416082A (zh) 2024-08-02
FI3474822T3 (fi) 2025-08-15
JP7221485B2 (ja) 2023-02-14
PL3474822T3 (pl) 2025-11-03
AU2023204117A1 (en) 2023-07-13
EP4295853A3 (en) 2024-03-06
JP2023033538A (ja) 2023-03-10
EP3474822B1 (en) 2025-07-09
DK3474822T3 (da) 2025-08-18
US12485131B2 (en) 2025-12-02
CN119139329A (zh) 2024-12-17
CA3024886A1 (en) 2018-01-04
JP2019519570A (ja) 2019-07-11
CN109475497A (zh) 2019-03-15
JP7407984B2 (ja) 2024-01-04
AU2017290703B2 (en) 2023-03-30
AU2017290703A1 (en) 2018-12-13
US20200138835A1 (en) 2020-05-07
JP2021143178A (ja) 2021-09-24
AU2023204117B2 (en) 2025-03-20
EP3474822A1 (en) 2019-05-01
CN114569547A (zh) 2022-06-03
EP4295853A2 (en) 2023-12-27
US20170368082A1 (en) 2017-12-28
US20230210873A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP6878473B2 (ja) ブリンシドフォビルの製剤
JP7359827B2 (ja) 治療薬のｃｎｓ送達
Collier et al. Evidence for luminal uptake of gentamicin in the perfused rat kidney.
TR201810815T4 (tr) Tnf-alfa antikorlarının farmasötik formülasyonları.
Frenken et al. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection
EP1991239A1 (en) Doxorubicin formulations for anti-cancer use
TW202128184A (zh) 酒精性肝炎之治療
Kim et al. Pharmacokinetics and four-week repeated-dose toxicity of hyaluronic acid and ketorolac combination following intra-articular administration in normal rats
Seligman et al. Single‐dose pharmacokinetics of sodium ferric gluconate complex in iron‐deficient subjects
HK40075964A (en) Formulations of brincidofovir
HK40105712A (en) Formulations of brincidofovir
PETERSEN et al. Digoxin–trimethoprim interaction
Diamond et al. Ameliorative effects of dietary protein restriction in chronic aminonucleoside nephrosis
Roberts et al. Pharmacokinetics of cephradine given intravenously with and without probenecid
US20220071938A1 (en) Treatment of hyperammonemia in patients with renal insufficiency
US20250017887A1 (en) Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
Brencher et al. Effect of Glycine, pyruvate, and resveratrol on the regeneration process of postischemic intestinal mucosa
KR20150030761A (ko) 화합물 1-(6-｛[6-(4-플루오로페닐)[1,2,4]트리아졸로[4,3-b]피리다진-3-일]술파닐｝-1,3-벤조티아졸-2-일)-3-(2-모르폴린-4-일에틸)우레아를 포함하는 항종양 조성물
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210428

R150 Certificate of patent or registration of utility model

Ref document number: 6878473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250